Kalydeco is a brand that offers a prescription medicine called ivacaftor for the treatment of cystic fibrosis (CF). This medicine is intended for people aged 1 month and older who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to Kalydeco. CF is caused by defects in the CFTR proteins, which can lead to an imbalance of salt and water in the lungs and the production of thick, sticky mucus.

Kalydeco targets the underlying cause by affecting the gating of CFTR proteins, allowing more chloride ions to move into and out of the cells. This helps keep a balance of salt and water in the lungs. While Kalydeco does not increase the number of CFTR proteins at the cell surface, it can help certain CFTR proteins work better.

It's important to consult with a healthcare provider for questions about Kalydeco treatment